Girinimbine

Girinimbine (Girinimbin) is a carbazole alkaloid with a variety of biological effects. Girinimbine can induce apoptosis , and has antitrypanosomal, antiplatelet activity, antibacterial activity, anti-inflammatory, antioxidant and antitumor activities . In Vitro Girinimbine (1-400 µM; 24-72 h) decreases the viability of HepG2 cells in 24, 48 and 72 h with IC 50 values of 61 µM, 56 µM, and 40 µM respectively. Girinimbine (10-100 µM; 24-48 h) increase of LDH leakage in both concentration- and time-dependent manner in HepG2 cells. Girinimbine (56 µM; 24-48 h) treatment results in DNA fragmentation and elevates levels of caspase-3 in HepG2 cells. HepG2 cells. Girinimbine (56 µM; 12-48 h) treatment also displays a time-dependent accumulation of the Sub-G0/G1 peak (hypodiploid) and caused G0/G1-phase arrest. Girinimbine shows a potent antitrypanosomal activitywith an IC 50 value of 10.16 µg/mL. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HepG2 cells Concentration: 1 µM, 10 µM, 50 µM, 100 µM, 200 µM Incubation Time: 24 h, 48 h and 72 h Result: Inhibited the proliferation of HepG2 cells in vitro in a dose- and time-dependent manner. Apoptosis AnalysisCell Line: HepG2 cells Concentration: 56 µM Incubation Time: 24 h, 48 h Result: Showed typical morphological features of apoptosis. Cell Cycle AnalysisCell Line: HepG2 cells Concentration: 56 µM Incubation Time: 12 h, 24 h, 48 h Result: Induced G0/G1-phase arrest in HepG2 cells. In Vivo Girinimbine (10-100 mg/kg; orally gavage; once) pretreatment helps limit total leukocyte migration, and reduced pro-inflammatory cytokine (IL-1β, TNF-α) levels in the peritoneal fluid. In vivo in zebrafish embryos, Girinimbine (20 μg/mL; 24 hours) shows significant distribution of apoptotic cells in embryos. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male ICR mice (25-35 g) treated with carrageenanDosage: 10 mg/kg, 30 mg/kg, and 100 mg/kg Administration: Orally gavage; once Result: Helped limit total leukocyte migration, and reduced pro-inflammatory cytokine levels in the peritoneal fluid. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet